Associated Papers
Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research.
De Sutter L et al.
Disease Models & Mechanisms, 2025
Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).
De Sutter L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Systematic review and meta-analysis of genomic alterations in acral melanoma.
Broit N et al.
Pigment Cell & Melanoma Research, 2022
35229492 (PubMed )
Supplement: PCMR-35-369-s002.pdf
Identification of New Tumor-Related Gene Mutations in Chinese Gastrointestinal Stromal Tumors.
Feng Y et al.
Frontiers in Cell and Developmental Biology, 2021
Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors.
Wang Y et al.
Translational Oncology, 2020
Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
Jilg S et al.
International Journal of Cancer, 2019
PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.
Gebreyohannes YK et al.
Clinical and Experimental Medicine, 2019
Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
Gebreyohannes YK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.
Na YS et al.
Oncotarget, 2017
Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Gebreyohannes YK et al.
Molecular Cancer Therapeutics, 2016
Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.
Van Looy T et al.
Clinical Sarcoma Research, 2014
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
Zebary A et al.
Journal of Dermatological Science, 2013
Select a paper to view details